XOMA Key Statistics, Chart & Performance
The current stock price of XOMA is 29.92 USD. In the past month the price decreased by -6.73%. In the past year, price increased by 18.82%.
XOMA Latest News, Press Relases and Analysis
XOMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About XOMA
Company Profile
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Company Info
XOMA ROYALTY CORPORATION
2200 Powell Street, Suite 310
Emeryville CALIFORNIA 94608 US
CEO: James Neal
Employees: 13
Phone: 15102047200
XOMA ROYALTY CORPORATION / XOMA FAQ
Can you describe the business of XOMA ROYALTY CORPORATION?
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
What is the current price of XOMA stock?
The current stock price of XOMA is 29.92 USD. The price increased by 9.96% in the last trading session.
Does XOMA ROYALTY CORPORATION pay dividends?
XOMA does not pay a dividend.
What is the ChartMill technical and fundamental rating of XOMA stock?
XOMA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How many employees does XOMA ROYALTY CORPORATION have?
XOMA ROYALTY CORPORATION (XOMA) currently has 13 employees.
Can you provide the upcoming earnings date for XOMA ROYALTY CORPORATION?
XOMA ROYALTY CORPORATION (XOMA) will report earnings on 2026-03-16, before the market open.
XOMA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to XOMA. When comparing the yearly performance of all stocks, XOMA is a bad performer in the overall market: 63.78% of all stocks are doing better.
XOMA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to XOMA. XOMA has a medium profitability rating, but doesn't score so well on its financial health evaluation.
XOMA Financial Highlights
Over the last trailing twelve months XOMA reported a non-GAAP Earnings per Share(EPS) of 0.75. The EPS increased by 135.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.96% | ||
| ROA | 3.75% | ||
| ROE | 9.14% | ||
| Debt/Equity | 0.87 |
XOMA Forecast & Estimates
10 analysts have analysed XOMA and the average price target is 65.79 USD. This implies a price increase of 119.89% is expected in the next year compared to the current price of 29.92.
For the next year, analysts expect an EPS growth of 153.97% and a revenue growth 73.62% for XOMA